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Background: Helicobacter pylori infection is the most common chronic bacterial infection around the world and an important cause of gastrointestinal disorders, which might be involved in the pathogenesis of some extragastrointestinal disturbances as well as changes in serum lipid profile. Hypolipemic properties of omega-3 fatty acids have been studied in several studies.
Objectives: The present study aimed to compare the effects of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) supplementation on the level of serum lipoproteins in H. pylori.
Patients and Methods: In a randomized, double-blinded, placebo-controlled clinical trial in Iran, 105 Helicobacter pylori were randomly allocated to receive 2 g of daily EPA (35 patients), DHA (35 patients), or medium-chain triglyceride (MCT) oil as placebo (33 patients) along with conventional tetra-drug H. pylori eradication regimen for 12 weeks.
Results: From 105 included patients, 97 (31 in EPA, 33 in DHA, and 33 in control groups) completed the study and were included in final analysis. The levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and the ratios of TG/HDL-C, TC/HDL-C, and LDL-C/HDL-C were not significantly different among the three groups, while the level of triglyceride (TG) was statistically different. DHA (-16.6 ± 30.34) and control (+ 15.32 ± 56.47) groups were statistically different with regard to changes in TG levels (P = 0.000).
Conclusions: There was no difference between the effects of 2 g of EPA or DHA supplementation for 12 weeks on the levels of total cholesterol, LDL-C, HDL-C, TC/HDL-C, TG/HDL-C, and LDL-C/HDL-C; however, it had a desirable effect on the level of TG in a way that the effect of DHA was clearer.
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1. Background
Helicobacter pylori, the most common cause of chronic bacterial infection worldwide (1), is the main etiologic factor of peptic ulcer and is responsible for several other gastrointestinal (GI) disorders (2). While about half of the world population are reported to be the carriers of this organism (3), the prevalence of the infection among the adult population in the Middle East and Iran have been re-ported to be 70% to 90% (2) and 69% (4), respectively. Com-plications of the infection depend on complex interactions between the bacteria and the host, e.g. infection virulence, genetics sequence, the age of the host, environmental fac-tors, and dietary habits (5). Several studies have suggested that H. pylori infection might be involved in the pathogen-esis of some extra-GI disturbances. Due to complications of H. pylori infection such as endothelial injury, smooth 
muscle proliferation, and local inflammation of blood ves-sel walls (1) and its effect on lipid metabolism (1, 2, 6), it is considered as a risk factor for cardiovascular diseases (7). The association of this bacteria with atherosclerotic dis-eases, gallbladder stone, dyspepsia, metabolic syndrome, type 1 diabetes mellitus, and insulin resistance have been reported in the studies conducted in Iran (8). Many stud-ies have shown that infection with H. pylori increases the levels of total cholesterol (TC), triglyceride (TG), low-den-sity lipoprotein cholesterol (LDL-C), Apo B, Lp (a), TC/high-density lipoprotein cholesterol (HDL-C), LDL-C/HDL-C, and decreases in the levels of HDL-C and Apo A-I, and therefore, is risk factor of coronary heart disease (CHD), coronary ar-tery disease (CAD), atherosclerosis, and stroke (1, 2, 6, 9, 10). Omega-3 fatty acids (N3FAs) have shown to be beneficial 
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due to their anti-inflammatory, antithrombotic, antiar-rhythmic, hypolipemic and vasodilatory properties (11). It has been noted that by suppressing the hepatic lipogen-esis, N3FAs influence lipid metabolism (12), prevent TG syn-thesis, and decrease production and secretion of very-low density lipoprotein (VLDL) (13). Furthermore, various stud-ies have shown that eicosapentaenoic acid (EPA) and doco-sahexaenoic acid (DHA) have different clinical effects on gene expression (14), blood pressure (15, 16), vascular func-tion (15), serum lipid profile (17) such as TG (18) and HDL-C (15), size of lipoprotein particles such as HDL-C, LDL-C, and VLDL (14, 18), serum glucose and insulin in hyperlipidemic male adults (17), inflammatory mediators (19, 20), mood disorders such as depression (21, 22), visual disorders (23-26), and cognitive disorders such as dementia (27).
2. ObjectivesGiven the high prevalence of H. pylori infection, abnor-mal serum lipid profile in patients with this infection, and the potential beneficial effects of N3FAs supplementation on the improvement of the patients infected with this bac-terium, this study aimed to compare the effects of EPA and DHA supplementation on the level of serum lipoproteins in those infected with H. pylori.
3. Patients and MethodsThis randomized, double-blinded, placebo-controlled clinical trial was performed in Tehran, Iran, during the winter of 2012. The population of the study included all adult patients, aged 20 to 60 years, who were admitted to the Gastrointestinal and Liver Disease Research Center of Iran University of Medical Sciences (Rasool Akram Hospi-tal). The under study patients were diagnosed with H. py-
lori infection by a gastroenterologist based on the patho-logic results of the stomach biopsy and met the eligibility criteria for participation in the study. These criteria includ-ed no history of treatment for H. pylori eradication, no gas-tric surgery, no history of peptic ulcer, no diseases causing inflammation or increased levels of inflammatory mark-ers such as diabetes mellitus, no cardiovascular diseases, and no pulmonary inflammations such as asthma. Other criteria were taking no medications other than those pre-scribed during the study period, taking no antibiotics or bismuth during the previous two months, taking no anti-oxidant supplements such as selenium, zinc, or beta-car-otene for at least three months prior to the study, taking no omega-3 supplements for at least three months prior to the study, no smoking, and having a body mass index (BMI) < 30 kg/m2. Exclusion criteria were changes in the type or dose of medication, changes in diet or daily physi-cal activity, any use of antioxidant supplements, and con-sumption of < 80% of supplements during the study pe-riod. First, among those who were diagnosed with H. pylori infection via the tissue culture, patients who volunteered to participate in the study and met the inclusion criteria were selected and invited to participate in the study. After 
attending the orientation session and obtaining written informed consent, the participants were enrolled. To de-termine the sample size, preliminary data were obtained. The quantitative dependent variables were determined ac-cording to the study of Barbosa et al. (28) and Saifullah et al. (29). There was an attempt to reject the null hypothesis of no difference in serum levels of lipoproteins among the three groups, at type I error level (α) of 0.05 and test pow-er (1-β) of 0.8. Therefore, a sample size of 30 patients per group was calculated but 35 patients in each group were selected, given that there would be 15% dropout during study. At the beginning of the study, information on socio-economic status of participants was collected by means of a questionnaire completed during an interview. For each participant, while wearing light clothes, body weight was measured, using a SECA scale with the precision of 0.5 kg. Each participant's height was measured in standing posi-tion without shoes, using a tape measure with precision of 0.5 cm. Finally, BMI was calculated (weight [kg]/ squared height [m2]). At the beginning of the study, 10 mL of blood samples were obtained from patients after 10 to 12 hours of fasting. Participants were randomly allocated to EPA, DHA, or control groups to receive 2 g of respectively morEPA, morDHA, or placebo daily for 12 weeks. Each morEPA and morDHA supplement had a purity of 75% containing 750 mg of N3FA (Minami-nutrition Co., Belgium). MorEPA con-tained 580 mg of EPA, 83 mg of DHA, and 87 mg of other N3FAs. MorDHA contained 63 mg of EPA, 465 mg of DHA, and 222 mg of other N3FAs. The placebo, used in the study, was medium-chain TG (MCT) oil, in 1-g capsules with a pu-rity of 100%, designed by Canadian company of Viva to spe-cifically resemble omega-3 capsules. Before the beginning of the study, all tins containing the capsules were coded by an independent person other than the researchers. Patients, in all three groups, received conventional tetra-drug eradication regimen of H. pylori including metroni-dazole (500 mg, bid), amoxicillin (1 g, bid), bismuth sub-citrate (240 mg, bid), and omeprazole (20 mg, bid) for 12 weeks. The report of daily dietary intake was collected by a 24-hour diet recall questionnaire once before the begin-ning of the study, then at fourth week, eighth week, and at the end of the study. The data were then analyzed by Nutri-tionist IV software. The reports of the level of physical ac-tivity were obtained through face-to-face interview using the international physical activity questionnaire (IPAQ) at the beginning and the end of the study. Patients were asked not to change their usual dietary intake and physi-cal activity during the study. During the 12-week interven-tion, the patients were called to resolve possible problems and ensure that the participants had consumed the drugs and supplements. At the end of week 12, the patients were asked to refer for H. pylori eradication check and related blood tests. All initial checks were repeated except height measurement. Serum lipoproteins were measured with calibrated instruments and in the following ways: TC and TG by enzymatic-colorimetric (photometric) method us-ing Parsazmun company kits (Iran); and LDL-C and HDL-C 
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by enzymatic selective protection/endpoint (turbidim-etry) method using Zist-Shimi company kit (Iran). The in-tra-assay and inter-assay precision (CV%) were respectively as follows: CHOD kit (for TC measurement), 0.61 and 1.22; GPO-PAP kit (for TG measurement), 1.82 and 1.04; LDL-C measurement kit, 1.50 and 1.97; and HDL-C measurement kit, 2.12 and 2.73. Data entry and statistical analysis were performed using SPSS 16 (SPSS Inc., Chicago, IL, USA). Quan-titative variables were reported with mean and standard deviation (mean ± SD) and their normal distribution was determined by Kolmogorov-Smirnov test. The difference in blood biochemical variables was compared in each group before and after the intervention. For variables with nor-mal distribution, paired-samples t-test and for variables other than those, Wilcoxon test were used. To compare quantitative variables between the three groups, analysis of variance (ANOVA) and Kruskal-Wallis tests were used for normally distributed variables or otherwise, respectively. Differences with P < 0.05 were considered statistically sig-nificant. The protocol of study complied with the Helsinki declaration and informed consent was obtained from each patient. The study was approved by the Ethics Committee of Public Health School of Iran University of Medical Sci-ences and was registered in Iranian Center of Clinical Trial Registration with the ID number of IRCT 201101122709N16.
4. ResultsFrom 105 enrolled patients, 97 (31 in the EPA, 33 in the DHA, and 33 in the control groups) completed the study. 
Eight patients were excluded from the study because of migration, adverse effects of drugs and supplements, or refusing to continue (Figure 1). The sex and age distribu-tion among study groups were as follows: EPA group, 12 males and 19 females (mean age, 35.54 ± 9.15 years); DHA group, 14 males and 19 females (mean age, 37.09 ± 10.28 years); and control group, 12 males and 21 females (mean age, 38.60 ± 10.92 years) (Tables 1 and 2). There were no significant differences among the intervention and con-trol groups regarding the distribution of sex, age, weight, daily dietary intake, and the level of physical activity at the beginning of the study; however, the BMI was sig-nificantly different (P = 0.04). Moreover, no significant change was observed in all three groups in the mean weight, BMI, daily dietary intake, and physical activity level during the study period (Tables 1 and 2). In addition, there were no significant differences among the three groups in the levels of biochemical variables at the base-line (Table 3). According to the findings of the study, there was no significant difference among the three groups in the average levels of TC, LDL-C, HDL-C, TC/HDL-C, TG/HDL-C, and LDL-C/HDL-C, while the level of TG was statistically different (P = 0.000). The post hoc analysis (Tukey's test) showed that DHA and control groups were different with regard to TG levels (Table 3). In the EPA group, there was a significant reduction in the mean serum levels of TC, TC/HDL-C, and TG/HDL-C at the end of the study in compari-son to the initial values (P = 0.035, P = 0.014, and P = 0.019, respectively), while the change in the mean levels of LDL-C, HDL-C, TG, and LDL-C/HDL-C were not significant. 
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Figure 1. CONSORT Statement 2010 Flow Diagram
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Table 1.  Distribution of Age, Weight, and Body Mass Index among Study Groups a
Variable EPA (n = 31) DHA (n = 33) Control (n = 33) P Value c
Age, y 54.35 ± 9.15 37.09 ± 10.28 38.60 ± 10.92 0.45
Weight, kgBefore intervention 68.11 ± 12.35 70.19 ± 9.92 73.81 ± 11.00 0.10After intervention 69.23 ± 11.24 72.09 ± 10.80 71.72 ± 11.42 0.21
P Value d 0.13 0.20 0.23 -
BMI, kg/m2Before intervention 24.17 ± 3.52 25.59 ± 3.23 26.22 ± 3.42 0.04After intervention 24.35 ± 3.72 25.85 ± 3.73 26.20 ± 3.09 0.05
P Valued 0.18 0.21 0.19 -a Abbreviations: EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; BMI, body mass index.c ANOVA test.d Paired-samples t-test.
Table 2.  Distribution of Sex and Physical Activity Variables in Three Groups a, b
Variable EPA (n = 31) DHA (n = 33) Control (n = 33) P Value c
SexMale 13 (37.1) 14 (40) 14 (40) 0.96Female 22 (62.9) 21 (60) 21 (60)
Physical activityMild 24 (77.4) 30 (90.9) 27 (81.8) 0.30Moderate 7 (22.6) 3 (9.1) 6 (18.2)a Abbreviations: EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid.b Data are presented as No. (%).c Chi-square test.
Table 3.  Distribution of Blood Biochemical Variables at the Beginning and the End of the Study a, b
Variable EPA (n = 31) DHA (n = 33) Control (n = 33) P Value
TC, mg/dLBaseline 164.09 ± 34.20 178.58 ± 48.25 170.62 ± 42.89 0.397At the end 156.06 ± 32.17 172.39 ± 39.42 172.94 ± 36.25 0.108Difference -8.03 ± 20.62 -6.19 ± 41.99 2.32 ± 26.40 0.348
P Value 0.035 0.418 0.611 -
TG, mg/dLBaseline 95.66 ± 27.14 111.16 ± 31.60 97.79 ± 29.04 0.080At the end 91.94 ± 20.41 95.10 ± 26.89 113.12 ± 59.72 0.141Difference -3.72 ± 19.13 -16.6 ± 30.34 15.32 ± 56.47 0.000
P Value 0.438 0.003 0.024 -
LDL-C, mg/dLBaseline 92.50 ± 23.14 100.10 ± 23.48 92.97 ± 24.56 0.367At the end 88.81 ± 18.49 98.39 ± 22.05 99.47 ± 24.58 0.104Difference -3.69 ± 18.99 -1.71 ± 26.40 6.50 ± 20.93 0.130
P Value 0.281 0.729 0.079 -
HDL-C, mg/dLBaseline 43.75 ± 10.46 45.71 ± 10.64 43.65 ± 11.78 0.703At the end 45.84 ± 10.68 49.26 ± 12.42 46.38 ± 11.30 0.450Difference 2.09 ± 10.06 3.55 ± 12.02 2.73 ± 8.76 0.855
P Value 0.248 0.111 0.078 -
TC/HDL, ratioBaseline 3.80 ± 0.50 3.92 ± 0.85 3.89 ± 0.70 0.943At the end 3.46 ± 0.52 3.54 ± 0.49 3.78 ± 0.41 0.022Difference -0.34 ± 0.69 -0.37 ± 0.98 -0.11 ± 0.15 0.393
P Value 0.014 0.014 0.362 -a Abbreviations: EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; BMI, body mass index; TC, total cholesterol; TG, triglyceride; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol.b Data are presented as Mean ± SD.
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Table 4.  Distribution of Blood Biochemical Variables at the Beginning and the End of the Study (con't) a, b
Variable EPA (n = 31) DHA (n = 33) Control (n = 33) P Value
TG/HDL, ratioBaseline 2.23 ± 0.57 2.50 ± 0.82 2.34 ± 0.93 0.402At the end 2.07 ± 0.50 2.00 ± 0.58 2.64 ± 2.42 0.024Difference -0.17 ± 0.40 -0.51 ± 0.77 -0.30 ± 2.09 0.053P value 0.019 0.000 0.224 -
LDL/HDL, ratioBaseline 2.14 ± 0.41 2.22 ± 0.44 2.17 ± 0.43 0.719At the end 1.97 ± 0.35 2.03 ± 0.29 2.11 ± 0.32 0.208Difference -0.16 ± 0.56 -0.20 ± 0.54 -0.05 ± 0.43 0.486
P Value 0.111 0.052 0.484 -a Abbreviations: EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; TG, triglyceride; LDL, low-density lipoprotein; and HDL, high-density lipoprotein.b Data are presented as Mean ± SD.
In the DHA group, there was a significant reduction in the mean serum levels of TG, TC/HDL-C, and TG/HDL-C at the end of the study in comparison to the initial values (P = 0.003, P = 0.014, and P = 0.000, respectively), whereas the levels of TC, LDL-C, HDL-C, and LDL-C/HDL-C did not change significantly. There was a significant increase in the serum level of TG (P = 0.024) in the control group (Tables 3 and 4).
5. DiscussionInfection with H. pylori can be treated using standard therapy in more than 80% of infected patients (30). The treatment regimen, examined in the present study, is based on a combination of two antibiotics and a proton pump inhibitor. The three-drugs regimen with a proton pump inhibitor, clarithromycin, and either amoxicillin or metronidazole, is the most commonly administered treat-ment regimen for the eradication of the infection; howev-er, the major reasons for the failure in eradication therapy are antibiotic resistance and intolerance due to secondary effects. There are several ways to reduce the chances of fail-ure in the treatment: detection of newer and more effec-tive drugs to kill the bacteria, immunization method (vac-cine) to stimulate host immune defenses, or extension of nutritional practices for infection control (5). Statistical analysis of Cochran’s and Mantel-Haenszel was applied, as there was the likelihood that the significant difference among the three groups, in BMI, would have an influence on the variables. The results of this analysis suggested that the mean difference in the BMI among three groups could not be a confounding factor in the interpretation of the findings. This study demonstrated that EPA or DHA supple-mentation significantly differed regarding their effect on the level of serum TG in patients with H. pylori infection; this difference was observed between DHA and control groups. Different effect of EPA and DHA on serum lipid pro-file had been demonstrated in some studies (17, 18). There was a significant reduction in TG level in comparison to the control value following the DHA treatment, while the 
decrease values in the EPA group failed to reach signifi-cance (18). Reduction in TG level in DHA supplemented group was more than in EPA group (15, 31, 32). Therefore, DHA might be more efficacious in improving the plasma lipid profile than EPA might be. Nonetheless, the findings of this study showed that the mean level of serum TG in-creased significantly in the control group. Some studies have shown that MCTs significantly increased serum TGs (33, 34). Parinyasiri et al. showed that six-months adminis-tration of daily dose of 4-g N FAs (containing EPA and DHA) in patients with IgA nephropathy resulted in a significant reduction in serum TG level, significant increase in HDL-C, and insignificant reduction in TC. In that study, the dose and duration of supplementation were two times of those in our study, and the basic concentration of the serum lev-els of TG and TC of the patients were higher than that of our study. Therefore, the mean difference between the be-ginning and the end of the study was higher and clearer than that of our study was (35). Maki et al. noticed that re-ceiving 4 g/d of N3FAs for six weeks in patients with essen-tial hypercholesterolemia caused a significant reduction in serum TG and significant increase in HDL-C and LDL-C levels while it had no effect on the serum TC level. In that study, the supplement dose was twice as much as our dos-age while the duration of supplementation was half of that in our study and the basic concentration of the serum levels of TC and LDL-C of the patients in that study were higher than those in our study were, which underlay the inconsistency between their findings with regard to TC and LDL-C with ours (36). The mechanism by which DHA might increase serum level of HDL-C is not known; howev-er, it can be related to change in activity of lipid transfer protein that is decreased after supplementation with N3FAs (17). Damsgaard et al. showed that addition of 5 mL of fish oil to diet of nine-month-old infants, for three months led to a significant elevation in serum TC and LDL-C and a significant reduction in serum TG while it had no effect on the serum HDL-C. Some results of that study were 
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inconsistent with ours. It is difficult to compare these re-sults with our results because the regulation of lipid me-tabolism might be different in infants. The observed in-creased cholesterol might not be caused by omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), but might be due to an increased intake of fat and cholesterol delivered by the fish oil (37). Clarke suggested that inges-tion of N3LCPUFA would affect lipid metabolism by sup-pressing hepatic lipogenesis, reducing hepatic TG output, and increasing fatty acid (FA) oxidation in the liver and muscle tissue, possibly via interaction with transcription factors that regulate the expression of genes encoding key regulatory proteins of lipid metabolism. Lowering TG con-centrations might decrease transfer of TG to LDL-C and re-moval of cholesterol from LDL-C, resulting in larger, more cholesterol-rich LDL-C particles (12). The mechanism of lowering effect of long-chain N3FAs on serum TG concen-trations has been attributed to a suppressed hepatic lipo-genesis with a concomitant reduction in the supply of FAs for TG synthesis and VLDL secretion, and to an enhanced clearance of VLDL in the liver or peripheral tissues (38-40). The mechanism that could illustrate the TG-lowering ef-fects of marine N3FAs has not been described well. An in-terpreting model can be at the level of gene transcription, which include several metabolic nuclear receptors such as hepatic X receptor, hepatic nuclear factor 4-α (HNF4-α), farnesoid X receptor (FXR), and peroxisome proliferator-activated receptors (PPARs). Each of these receptors is reg-ulated by sterol regulatory element-binding protein-1c (SREBP-1c), the main genetic factor controlling the lipogen-esis. The N3FAs show TG-lowering effects via hepatic lipo-genesis suppression, decreasing the SREBP-1c level, upreg-ulation fat oxidation in the liver and skeletal muscle by PPAR activation, and increasing the flow of glucose to gly-cogen by downregulation of HNF 4-α. The N3FAs have more TG-lowering effects than omega-6 FAs have, through down-regulation of proteins coding the genes that stimulate lipid synthesis and upregulation of proteins coding the genes that stimulate FAs oxidation. Moreover, these FAs can act via increasing the uptake of postprandial chylomi-cron by decreasing VLDL secretion and direct stimulation of lipoprotein lipase (LPL) activity. Sum of these effects sup-ports the consumption of N3FAs as an effective clinical fac-tor in treatment of hypertriglyceridemia (41). Taziki et al. (42) showed that in patients on hemodialysis, daily intake of 2 g of N3FAs, containing EPA and DHA, for 12 weeks caused a significant reduction in serum TG and increase in HDL-C, while it had no significant effect on the serum lev-els of TC and LDL-C. In that study, the dose of supplement and intervention duration were similar to those in our study; the cause of ineffectiveness of supplementation on some serum lipid levels was mentioned to be the adminis-tration of rather low dose of N3FAs (2 g/d) (42). Most evi-dence suggests that N3FAs prevent TG synthesis, reduce the production and secretion of VLDL particles and in-creases the conversion of VLDL to LDL-C via decreasing li-pogenesis by decreasing the enzymatic conversion of ace-
tyl-CoA to FAs, increasing β-oxidation of FAs, inhibiting both phosphatidic acid phosphatase/phosphohydrolase (PAP) (an enzyme that catalyzes the reaction of converting phosphatidic acid to diacylglycerol) and diacylglycerol ac-yltransferase (DGAT) (an enzyme that catalyzes the final step in TG synthesis), increasing the degradation of apoli-poprotein B, and increasing LPL activity (13). Trials in hu-mans, using mixtures enriched in EPA and DHA, have sug-gested that these two FAs have different effects on serum lipids. More precisely, EPA selectively lowers TGs whereas DHA selectively lowers cholesterol (43, 44); however, very high doses of N3FAs (equal to 12-24 g/d) were consumed in these studies. These findings were in contrast with our findings. In a study, Mori and Woodman stated that hu-man studies show that DHA might be more effective in in-creasing HDL-C and fasting and postprandial TG (15) while in our study, these N3FAs on serum had no difference in af-fecting level of HDL-C; however, there was favorable effect on serum TG, in a way that the effect of DHA was clearer. In another study, Mori et al. suggested that daily intake of 4 g of EPA, DHA, or placebo for six weeks, had no differential effect on serum TC and HDL-C while both of them de-creased serum TG and serum level and particle size of LDL-C increased in DHA receiving group (17). The results of that study had more similarity with ours. The difference of the results of above studies could be result of the difference in amount of consumed N3FA, the model of omega-3 presen-tation (fish, fish oil, or purified oil), or patient's lipoprotein phenotype (17). In summary, 2 g of either EPA or DHA supplementation for 12 weeks had no significant effect on the levels of TC, LDL-C, HDL-C, TC/HDL-C, TG/HDL-C, and LDL-C/HDL-C. How-ever, it had a desirable effect on the level of TG in patients infected with H. pylori. The present study was the first to compare the effects of EPA and DHA on lipid profile in infected patients whose information regarding poten-tial confounding variables including dietary intake and physical activity level were available. Nevertheless, this study had some limitations. First, several patients partici-pating in the intervention were excluded from the study. The second limitation was lack of plasma levels measure-ment of N3FAs for better controlling the patients’ com-pliance. Moreover, frequent inclusion criteria, especially having no metabolic diseases, taking no supplements of N3FAs and antioxidant supplement, and no previous his-tory of infection, led to further reduction in the number of eligible patients for the study and hampered the dis-ease finding process. Finally, it is suggested to perform similar studies with larger number of patients and lon-ger study period for a better comparison of the effects on serum lipids. Another research study should be con-ducted with different doses of N3FAs to investigate dose-related effects of N3FAs on lipid markers and plasma con-centration measurement of N3FAs after the supplement intake to ensure the compliance rate of supplementation and effective dose of absorption, which would explain the mechanism of the compounds.
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